Oppenheimer set a $10.00 price objective on Mesoblast (NASDAQ:MESO) in a research note published on Tuesday morning, TipRanks reports. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for Mesoblast’s Q1 2020 earnings at ($0.03) EPS, Q2 2020 earnings at ($0.21) EPS, Q3 2020 earnings at ($0.09) EPS, FY2020 earnings at ($0.61) EPS, Q1 2021 earnings at ($0.17) EPS, Q2 2021 earnings at ($0.06) EPS, Q3 2021 earnings at ($0.03) EPS, Q4 2021 earnings at $0.05 EPS, FY2021 earnings at ($0.21) EPS and FY2022 earnings at $0.98 EPS.
A number of other equities research analysts have also issued reports on MESO. Maxim Group reaffirmed a buy rating and set a $16.00 price objective on shares of Mesoblast in a report on Wednesday, June 12th. Zacks Investment Research lowered shares of Mesoblast from a buy rating to a hold rating in a report on Friday, September 6th. ValuEngine raised shares of Mesoblast from a hold rating to a buy rating in a report on Tuesday. Chardan Capital set a $6.00 price objective on shares of Mesoblast and gave the company a hold rating in a report on Friday, August 30th. Finally, HC Wainwright set a $7.00 price objective on shares of Mesoblast and gave the company a buy rating in a report on Friday, August 30th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $11.25.
MESO traded up $0.58 during trading on Tuesday, reaching $7.33. 608 shares of the company traded hands, compared to its average volume of 43,361. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.92 and a current ratio of 1.41. Mesoblast has a 12-month low of $3.35 and a 12-month high of $8.78. The firm has a fifty day simple moving average of $5.06 and a 200 day simple moving average of $5.09. The company has a market cap of $572.56 million, a P/E ratio of -7.89 and a beta of 1.77.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley lifted its holdings in Mesoblast limited (NASDAQ:MESO) by 284.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the quarter. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 at the end of the most recent quarter. Institutional investors own 2.76% of the company’s stock.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Featured Story: Day Trading
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.